|
|
|
|
||
Strong Buy
ASCO will be the catalystThe ASCO presentation of P3 results is to the scientific community and can fix the problems that happened in the botched release of preliminary data in Feb. The data looks very good for approval and DCTH could easily have gone to a 200 million valuation on it but slipped. I think there are funds who will see value and take positions prior to the ASCO presentation. Looking at 20s again in summer after ASCO. |
return to message board, top of board |